TORONTO, Jan. 7, 2025 /PRNewswire/ — Four Seasons, the world’s leading luxury hospitality company, announces the appointment of Keisha Smith as Executive Vice President and Chief People and Culture Officer, effective January 6, 2025. Based at the company’s corporate office in Miami, Keisha joins the Executive Leadership Team and reports directly to Four Seasons President… Continue reading Four Seasons Appoints Keisha Smith as Executive Vice President and Chief People and Culture Officer
Tag: Morgan
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
The Keynote Address, entitled “Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD,” will be presented at 10:30AM PT on Sunday January 12th, 2025 Prof. David Feifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, is an international thought leader in the interventional psychiatry space NRx Pharmaceuticals… Continue reading HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
China exports push Nippon Steel to seek growth in US, India after blocked deal
“To be a ‘truly’ global steel producer, greater production capacity above current state is likely required,” said Wood Mackenzie’s Lundin. Nippon Steel is poised to expand its operations in the U.S. and India as it hunts for growth and protection from cheap Chinese exports after its bid for U.S. Steel was blocked by the White… Continue reading China exports push Nippon Steel to seek growth in US, India after blocked deal
Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference
HONG KONG and SAN FRANCISCO, Jan. 6, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place on January 13, 2025, in San Francisco, California. The company’s founder, chairwoman, president, and CEO, Dr. Michelle Xia will share the… Continue reading Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON, Jan. 6, 2025 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on the… Continue reading Danaher to Present at J.P. Morgan Healthcare Conference
F&G Annuities & Life Prices Junior Subordinated Notes Offering
DES MOINES, Iowa, Jan. 6, 2025 /PRNewswire/ — F&G Annuities & Life, Inc. (NYSE: FG) (“F&G”) today announced that it priced a public offering of $375 million aggregate principal amount of its 7.300% junior subordinated notes due 2065 (the “notes”). The offering is expected to close on January 13, 2025, subject to satisfaction of customary closing… Continue reading F&G Annuities & Life Prices Junior Subordinated Notes Offering
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take… Continue reading Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 6, 2025 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key… Continue reading Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Waystar to Present at J.P. Morgan Healthcare Conference
LEHI, Utah and LOUISVILLE, Ky., Jan. 6, 2025 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PT. Waystar will provide a live webcast… Continue reading Waystar to Present at J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed… Continue reading Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference